Relative Bioavailability of Three Different Oral Formulations of BI 764198 Including the Investigation of Food Effect on the Tablet Formulation in Healthy Male and Female Subjects (an Open-label, Randomised, Four-way Crossover Trial)
Latest Information Update: 05 Aug 2025
At a glance
- Drugs BI 764198 (Primary)
- Indications Focal segmental glomerulosclerosis; SARS-CoV-2 acute respiratory disease
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 18 Jul 2025 Status changed from active, no longer recruiting to completed.
- 04 Jun 2025 Status changed to active, no longer recruiting.
- 09 May 2025 New trial record